For instance, the inhibition of PI3K/AKT/mTOR pathway with specific targeting agents reduced PD-L1 levels in NSCLC cells; in particular the authors of this study reported that PD-L1 expression is dependent from mTOR signaling and then pharmacological inhibition of mTOR by rapamycin or AZD8055 markedly reduced PD-L1 level [91]. This evidence concerns the gene PIK3CA and non-small cell lung carcinoma.